Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Adalimumab vs placebo as add-on to Standard Therapy for autoimmune Uveitis: Tolerability, Effectiveness and cost-effectiveness-a protocol for a randomised controlled trial (ASTUTE trial).

Hazell M. et al, (2024), BMJ Open, 14

Population screening requires robust evidence-genomics is no exception.

Turnbull C. et al, (2023), Lancet

Cost-effectiveness of genetic-based screening strategies for maturity-onset diabetes of the young.

Kovács G. et al, (2023), Per Med

Lessons learned from the application of the HEcoPerMed guidance to three modeling case studies.

Nagy B. et al, (2023), Per Med

Cost-effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK.

Koleva-Kolarova R. et al, (2023), Per Med

Cost–effectiveness and budget impact analysis of screening strategies for maturity-onset diabetes of the young in three European countries

Szilberhorn L. et al, (2023), Personalized Medicine

Long-term cost-effectiveness of a melanoma prevention program using genomic risk information compared with standard prevention advice in Australia.

Law CK. et al, (2023), Genet Med

Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation

Koleva-Kolarova R. et al, (2023), Personalized Medicine

Budget impact and transferability of cost–effectiveness of DPYD testing in metastatic breast cancer in three health systems

Koleva-Kolarova R. et al, (2023), Personalized Medicine

Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19·67 million people and evaluation of model performance against seven other risk prediction models.

Liao W. et al, (2023), Lancet Respir Med, 11, 685 - 697

Cost-effectiveness of alternative NTRK testing strategies in cancer patients followed by histology-independent therapy with entrectinib: an analysis of three European countries.

Vellekoop H. et al, (2023), Per Med, 20, 321 - 338

HEcoPerMed, personalized medicine from a health economic perspective: lessons learned and potential opportunities ahead.

Rutten-van Mölken M. et al, (2023), Personalized medicine, 20, 299 - 303

Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.

Harris J. et al, (2023), Health Technol Assess, 27, 1 - 257

Economic Evaluation in Genomic and Precision Medicine

BUCHANAN J., (2023)

Introduction to economic evaluation in health sciences

Mitropoulou C. et al, (2023), Economic Evaluation in Genomic and Precision Medicine, 1 - 14

Preface

Mitropoulou C. et al, (2023), Economic Evaluation in Genomic and Precision Medicine, xiii - xiv

Using “big data” for economic evaluations in genomics

Wordsworth S. et al, (2023), Economic Evaluation in Genomic and Precision Medicine, 113 - 121

Impact of video-assisted thoracoscopic lobectomy versus open lobectomy for lung cancer on recovery assessed using self-reported physical function: VIOLET RCT.

Lim E. et al, (2022), Health Technol Assess, 26, 1 - 162

Integrating genome-wide polygenic risk scores and non-genetic risk to predict colorectal cancer diagnosis using UK Biobank data: population based cohort study.

Briggs SEW. et al, (2022), BMJ, 379

Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features.

Robbe P. et al, (2022), Nat Genet

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?